At a glance
ClinicalIndex Comparison RecordPhase 2Active· 53 enrolled
Drug / intervention
Binimetinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol Z1A: Binimetinib in Patients With Tumors (Other Than Melanoma) With NRAS Mutations
In Brief
A Phase 2 clinical trial evaluating Binimetinib for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 53 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation. Binimetinib blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth when an NRAS mutation is present. Researchers hope to learn if binimetinib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
20172018201920202021202220232024202520262027
Enrollment StartMay 2016
Primary CompletionMay 2019
First PostedJun 2020
TodayJul 2026
Study CompletionMar 2027
First PostedJun 19, 2020
Enrollment StartMay 31, 2016
Primary CompletionMay 3, 2019
Study CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.0 years ago
Interventions
Binimetinibdrug
Given PO